Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study

The aim of this study was to determine the dose-limiting toxicities (DLTs) and maximum tolerated dose (MTD) of bortezomib plus docetaxel in patients with anthracycline-pretreated advanced/metastatic breast cancer. Forty-eight patients received up to eight 21-day cycles of docetaxel (60–100 mg m(−2)...

Descripción completa

Detalles Bibliográficos
Autores principales: Awada, A, Albanell, J, Canney, P A, Dirix, L Y, Gil, T, Cardoso, F, Gascon, P, Piccart, M J, Baselga, J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2008
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2391111/
https://www.ncbi.nlm.nih.gov/pubmed/18454159
http://dx.doi.org/10.1038/sj.bjc.6604347

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2391111/
https://www.ncbi.nlm.nih.gov/pubmed/18454159
http://dx.doi.org/10.1038/sj.bjc.6604347

Ejemplares similares